One of the highlights of the Clínic-IDIBAPS participation in the European Society for Medical Oncology (ESMO) 2024 Congress was Dr. Josep M. Llovet’s1
A study promoted by SOLTI and published in Nature Communications describes the tumour biology associated with the activity of the drug patritumab der1
This year, FERO will contribute €200,000, with which it will seek to provide structural and sustained support for the Molecular Diagnostics Programme1
On 27 June 2024, a social return event was held at the TV3 facilities, thanking the public for the television marathon devoted to cancer.
The DEFINITIVE project, led by IDIBAPS, will be conducted across 44 hospitals in a total of 7 European and associated countries to demonstrate that u1
